China Resources Pharmaceutical (03320.HK): China Resources Double-Crane's net profit attributable to owners for the first half of the year was approximately 975 million yuan, a decrease of 6.79% year-on-year.

The Zhongtong Finance APP reported that China Resources Pharmaceutical (03320.HK) announced the mid-term performance of Huarun Shuanghe in 2025, with total operating income of approximately 5.7415 billion yuan, a year-on-year decrease of 3.16%; the net profit attributable to shareholders of the listed company was approximately 975 million yuan, a year-on-year decrease of 6.79%; basic earnings per share was 0.9480 yuan, and a cash dividend of 1 yuan (including tax) per 10 shares.